Overview

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

Status:
Unknown status
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Functional Genetics Inc.
Collaborator:
United States Department of Defense
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins